Sign In

News Story

ACS CAN statement on appointment of Ned Sharpless, MD, as acting FDA commissioner

Sharpless will be replaced in his current role as NCI director by Doug Lowy, MD

The White House has announced its intention to appoint Ned Sharpless, MD (pictured here), current director of the National Cancer Institute (NCI), as acting commissioner of the Food and Drug Administration (FDA). Doug Lowy, MD, current deputy director at NCI, will take over as acting director.

Following is a statement from Lisa Lacasse, president of the American Cancer Society Cancer Action Network (ACS CAN):  

“Dr. Sharpless has demonstrated extraordinary leadership at NCI and has been a strong ally in the fight against cancer. While his vision and direct engagement with the cancer community will be sorely missed at NCI, Dr. Sharpless is well-positioned to lead the FDA forward along with Secretary Azar.

“With his exceptional perspective and experience in cancer research, Dr. Sharpless will be able to continue FDA’s work prioritizing the review and approval of innovative therapies that have the potential to cure diseases like cancer. It will also be vital that Dr. Sharpless advance and implement policies previously endorsed by outgoing-Commissioner Gottlieb aimed at curtailing the soaring rates of youth tobacco use, especially e-cigarettes.

“We are also pleased to hear about the appointment of Dr. Doug Lowy as acting director of NCI. Dr. Lowy has been a longtime champion of cancer issues as he returns to head the institute once again.

 “ACS CAN looks forward to working with both Dr. Sharpless and Dr. Lowy in their new roles.”

back to top